View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 27, 2021

AstraZeneca and Sputnik Light Covid vaccines show antibody growth in study

Nearly 85% of the participants had a four-times or greater rise in neutralising antibodies against the SAR-CoV-2 S-protein.

The Russian Direct Investment Fund (RDIF) has reported that a combination of AstraZeneca’s Covid-19 vaccine with the Sputnik Light vaccine showed robust neutralising antibodies growth in a clinical trial in the Republic of Azerbaijan.

AstraZeneca developed the Covid-19 vaccine in partnership with the University of Oxford.

The Sputnik Light vaccine is based on human adenovirus serotype 26, which is the first component of the Sputnik V Covid-19 vaccine.

The trial was launched in Azerbaijan in February this year and has so far enrolled 100 subjects.

The latest data was obtained from the first 20 subjects in the trial, who were given both components of the vaccine cocktail.

AstraZeneca’s vaccine was administered as the first component while Sputnik Light was given as the second shot after 29 days.

According to the initial virus neutralising activity results from the trial, a four-times or higher rise in neutralising antibodies to the spike protein (S-protein) of the SARS-CoV-2 virus was reported in 85% of the subjects on the 57th day of the trial.

The first collaboration of this kind concluded in December 2020.

RDIF, the Gamaleya Center, AstraZeneca and R-Pharm entered a memorandum of intent to carry out a clinical trial assessing the safety and immunogenicity of a combination of AstraZeneca vaccine and the first component of Sputnik V.

According to the results of interim analysis, the combination had shown to induce antibodies to the SARS-CoV-2 S-protein in all the trial subjects.

The vaccine cocktail was also found to have a greater safety profile without any serious adverse events or cases of Covid-19 infection after vaccination.

Apart from Azerbaijan, trials of a vaccine combination are progressing under an international programme in UAE and Russia.

Regulatory approval to carry out the trials has been granted in Belarus.

Separately, the RDIF reported that the Sputnik Light vaccine obtained emergency use authorization from the Egyptian Drug Authority (EDA) to expedite vaccination in the country’s population and create herd immunity in a reduced timeframe.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena